On March 24, Qingdao Haier Biomedical Co.Ltd(688139) disclosed in the annual report of 2021 that the upgrading of the company’s Internet of things continued to deepen, focusing on the two digital scenarios of “life science and medical innovation”. Through increasing the R & D of science and innovation, deepening the global layout, strengthening the construction of organizational capacity, the company promoted the upgrading of its business model to “product + service”, and achieved high-quality development in the complex external environment throughout the year.
In recent years, Qingdao Haier Biomedical Co.Ltd(688139) by continuously deepening the upgrading strategy of landing Internet of things and strengthening the customization ability of scenario scheme, Qingdao Haier Biomedical Co.Ltd(688139) has provided sufficient kinetic energy for the sustainable development of scenario ecology and performance of Building Internet of things. During the reporting period, the company’s overall performance continued a high growth trend, achieving a sales revenue of 2.126 billion yuan, a year-on-year increase of 51.63%; The total profit was 961 million yuan, a year-on-year increase of 126.49%; The net profit attributable to the parent company was 845 million yuan, a year-on-year increase of 121.82%. Among them, the revenue of Internet of things solutions business was 668 million yuan, a year-on-year increase of 138.11%, and its proportion in the total revenue increased from 20.01% in 2020 to 31.42%; The proportion of service revenue increased from 3.02% in 2020 to 10.84% in the reporting period, realizing double growth.
four business scenarios maintain high growth, and the “product + service” mode is gradually taking shape
Based on the diversified needs of users, the company continues to improve the ability of full scenario and full cycle solutions to meet the “personalized needs of users”, and gradually realize the transformation and upgrading of business model from product hardware sales to “product + service” solutions while ensuring the leadership and sustainability of customized solutions. Focusing on the diversification of users, the enrichment of solutions and the globalization of business, we made continuous breakthroughs and innovations. Qingdao Haier Biomedical Co.Ltd(688139) overall business continued to develop well. The four sectors of blood safety, drug and reagent safety, sample safety and vaccine safety achieved year-on-year growth of 266.32%, 49.26%, 21.78% and 102.71% respectively.
In the field of blood safety, scheme replication and innovation go hand in hand. Smart blood city network is replicated and promoted in Hubei, Zhejiang and other places, and iterative innovation of solutions for multiple segmentation scenarios such as hospitals and blood stations. By seizing the opportunity to sink users, the safety scene of drugs and reagents has been continuously deepened in the Chinese and foreign markets, effectively breaking through the user groups in the Americas, Asia Pacific and other regions. For the sample safety scenario, the company strives to expand the diversity of biopharmaceutical users, improve the richness of new scenarios such as biological culture and centrifugal preparation, and quickly replicate and expand under the trend of digital upgrading of the industry. The company promoted the replication of smart vaccine city network and scheme iteration, built more than 4000 smart vaccine vaccination points, innovated the mobile vaccination service mode, and built the great wall of national immunization.
At the same time, Qingdao Haier Biomedical Co.Ltd(688139) by continuously consolidating and deepening the advantages of global network channels, realized the synchronous and high-quality development of domestic and foreign markets, and the revenue increased by 60.25% and 39.34% respectively year-on-year. In terms of the Chinese market, users expand in three ways: breadth, depth and viscosity, vertically build a multi-level network system, and continuously cultivate in accordance with the user groups of hospitals, disease control, biopharmaceutical companies and university scientific research, so as to expand the demand from single scenario to multi scenario and conventional services to value-added services, and comprehensively deepen the full scenario and full cycle user services. In terms of overseas markets, we deepened the dual layout of “network + localization” and expanded the “circle of friends” of international organizations. During the reporting period, 208 overseas distribution networks were added, with a total of more than 500. We also established cooperative relations with more than 20 international organizations and continuously delivered vaccine and immunization projects in many overseas countries. With the continuous deepening and breakthrough of new user channels, the revenue of large projects and distribution business increased by 67.68% and 26.05% respectively year-on-year.
based on science and technology innovation, focusing on the two scenarios of “endogenous + extension” to accelerate the diversified layout of industries
The development of digital economy has brought about the expansion of user scenarios. With the company’s continuous innovative practice in the field of biosafety in recent years, in order to better serve users, the company combines its own advantages and condenses core resources, further focuses on the two major fields of “life science and medical innovation”, and accelerates the implementation of diversified industrial layout with the support of independent R & D innovation and organizational capacity-building.
In 2021, relying on the open innovation system of “field → laboratory → market”, the company supports business expansion, mode upgrading and long-term development, and provides a continuous endogenous driving force for the construction of digital scene ecology in the two fields of “life science and medical innovation”. In 2021, the company’s R & D investment reached 236 million yuan, a significant increase of 56.79% over the same period last year. The company continued to produce original technologies. In 2021, it successively broke through the core technologies such as high cooling capacity Stirling ultra-low temperature refrigeration technology, biological culture, centrifugal preparation and so on, so as to realize the continuous enrichment of product categories. The integration of technological innovation such as Internet of things, aiot and automation provides platform support for scenario scheme customization and user delivery capability improvement. Through the open mechanism of “creating win-win and sharing”, Qingdao Haier Biomedical Co.Ltd(688139) gathered ecological parties to jointly create aviation temperature control scenarios, and efficiently obtained ctsoa, MDA certificates and IATA codes, laying a solid foundation for the endogenous expansion of business scenarios. During the reporting period, the number of Qingdao Haier Biomedical Co.Ltd(688139) new applications and patents obtained increased by more than 60% year-on-year. The cumulative number of patents obtained reached 539, 33 software copyrights, and 19 national, industrial and group standards and technical specifications were led or participated in.
In terms of organizational capacity-building, Qingdao Haier Biomedical Co.Ltd(688139) adheres to the stable construction of core management team, and continuously stimulates internal potential through diversified mechanisms such as equity incentive, so as to lay a solid talent foundation for long-term and high-quality development. In addition, Qingdao Haier Biomedical Co.Ltd(688139) actively tried to use capital means to make collaborative innovation on the basis of the acquisition of the three great undertakings of Chongqing, build Haier’s blood technology ecological brand, and is committed to realizing the expansion from the scene of blood component separation to the scene of blood component preservation and then to the scene of blood fluid treatment through tackling the problem of “neck sticking”, so as to bring leapfrog acceleration to the in-depth development of blood safety scene.
In the future, Qingdao Haier Biomedical Co.Ltd(688139) will also comply with the new trend of digital economy development, continue to focus on the two major fields of “life science and medical innovation”, adhere to independent innovation and green and low-carbon development, focus on the upgrading of “product + service” business model and the dual industrial layout of “endogenous + extension”, build a digital scene ecology, consolidate core competitiveness and comprehensive strength, and promote the high-quality and sustainable development of the company.
